Tissue Factor Activity and Ischemia

Access this open-access article that describes a relationship between plasma TF levels, cancer-related ischemia, and elevated D-dimer: Gon Y, Kawano T, Kitano T, et al. Tissue factor activity and 1-year mortality in patients with active cancer and acute ischemic stroke: findings from the SCAN study. Res Pract Thromb Haemost. 2026;10(1):103347. doi: 10.1016/j.rpth.2026.103347. PMID: 41695667; PMCID: […]

Comments (0)

Arterial Thrombosis

May 15 2026

george

Perioperative Management of Antiphospholipid Syndrome Study

Click here for the open-access article, Paquette M, Miranda S, Xu Y, et al. Perioperative management of antithrombotic therapy in patients with thrombotic antiphospholipid syndrome. Blood Adv. 2026;10(9):3218–28. doi: 10.1182/bloodadvances.2026019610. PMID: 41843780; PMCID: PMC13136740. Abstract Patients with thrombotic antiphospholipid syndrome (APS) frequently require interruption of anticoagulation for invasive procedures; however, data to guide the perioperative […]

Comments (0)

Anticoagulant Therapy

May 8 2026

george

Aspirin Prophylaxis

The question appeared on the Diagnostic Equity site, paraphrased with the approval of site proprietor Tamara Lobban-Jones: “I’ve heard that some people take a ‘ton of baby aspirin.’ My doc told me to take only one a day. Does taking multiple tablets help with clotting? What does taking one aspirin do to the blood, and […]

Antiplatelet Therapy

Plasminogen Deficiency and Ligneous Conjunctivitis

Dr. Amy Shapiro, Medical Director and CEO, Innovative Hematology & Indiana Hemophilia & Thrombosis Center, provided a THSNA “rare disorders presentation, Diagnosing plasminogen deficiency–clinical and laboratory considerations. Abstract: Type 1 plasminogen deficiency (PLGD) or hypoplasminogenemia is an ultrarare disorder caused by pathogenic variants in the PLG, resulting in decreased functional and antigenic plasminogen levels. PLGD […]

Thrombophilia

Case: Essential Thrombocythemia

Here is a February 16, 2026, question addressed to the Diagnostic Equity website: “I have essential thrombocythemia (ET). Can I live a normal life, and will my labs be a barometer for how I am doing?” Here is the response excerpted by colleague Kathryn Golab, DCLS: ET is a disorder of the early blood-forming cells […]

Arterial Thrombosis

Letter to 2024 NEJM Links Adenoviral Anti-PF4 to VITT

Click here for the full news release from Flinders University News: New research, led by Flinders University and international experts, has finally uncovered how a rare blood-clotting condition can occur after some COVID-19 adenovirus-based vaccines or after a natural adenovirus infection. First paragraph: To the Editor: Disorders caused by antibodies against platelet factor 4 (PF4) gained […]

Arterial Thrombosis

Review: Neutrophil Extracellular Traps (NETs) in Thrombosis

This open-access review scans literature associating NETs with coagulation: Huang G, Wu H, Lin B, et al. Targeting neutrophil extracellular traps: a new strategy for the treatment of acute ischemic stroke based on thrombolysis resistance. Semin Thromb Hemost. 2026;52:80-91. doi: 10.1055/a-2609-3457. PMID: 40461018; PMCID: PMC12799313. Abstract Acute ischemic stroke (AIS) is a life-threatening thrombotic disorder, […]

Arterial Thrombosis

Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal

Navigate to this open-access article describing andexanet alfa reversal of LMWH: van Haaps TF, Benz AP, Xu L, Middeldorp S, Eikelboom JW, et al. Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin. Res Pract Thromb Haemost. 2025;9:103191. doi: 10.1016/j.rpth.2025.103191. PMID: 41141842; PMCID: PMC12552982. Abstract Background Andexanet alfa (andexanet) is the only approved reversal […]

Comments (1)

Anticoagulant Therapy

Dec 26 2025

george

Analytical Dilemmas in Lupus Anticoagulant Testing

Click here to read an open-access review by Moore GW. Analytical Dilemmas in Lupus Anticoagulant Testing. Explor Immunol. 2023;3:300–24 DOI: https://doi.org/10.37349/ei.2023.00104 Abstract Accurate lupus anticoagulant (LA) detection is crucial to antiphospholipid syndrome (APS) diagnosis. Detection is based on LA functional behavior in coagulation assays irrespective of epitope specificity. LA screening tests employ dilute phospholipids to […]

Arterial Thrombosis

Discussion of Phase I Data on a Unique anti-VWF Thrombolytic

A summary by Dr. Wolfgang Miesbach: A potential landmark thrombolytic innovation presented at ASH 2025. Thrilled by the exciting Phase 1 data presentation by Marie Scully and co-authors on TGD001, a groundbreaking novel von Willebrand factor (VWF)-targeting thrombolytic: First-of-its-kind mechanism: TGD001 is an antibody-enzyme fusion protein—specifically, an anti-VWF antibody fragment fused to a urokinase catalytic domain. […]

Comments (0)

Arterial Thrombosis

Arterial Thrombosis

Tissue Factor Activity and Ischemia

Perioperative Management of Antiphospholipid Syndrome Study

Aspirin Prophylaxis

Plasminogen Deficiency and Ligneous Conjunctivitis

Case: Essential Thrombocythemia

Letter to 2024 NEJM Links Adenoviral Anti-PF4 to VITT

Review: Neutrophil Extracellular Traps (NETs) in Thrombosis

Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal

Analytical Dilemmas in Lupus Anticoagulant Testing

Discussion of Phase I Data on a Unique anti-VWF Thrombolytic

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question